Browsing by title

Now showing items 4071-4090 of 4660

    • Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model. 

      Richartz, N; Duthil, E; Ford, A; Naderi, EH; Bhagwat, S; et al. (AMER SOC HEMATOLOGY, 2019-11-12)
      Acute lymphoblastic leukemia (ALL) develops in the bone marrow in the vicinity of stromal cells known to promote tumor development and treatment resistance. We previously showed that the cyclooxygenase (COX) inhibitor ...

    • Targeting deficient DNA damage repair in gastric cancer. 

      Young, K; Starling, N; Cunningham, D (2016-09)
      Introduction Over recent years our understanding of DNA damage repair has evolved leading to an expansion of therapies attempting to exploit DNA damage repair deficiencies across multiple solid tumours. Gastric cancer has ...

    • Targeting DNA damage response in oesophagogastric cancers 

      Starling N; Cartwright, E; Starling, N (Institute of Cancer Research (University Of London), 2023-05-30)
      A subset of patients with oesphophagogastric (OG) adenocarcinomas are characterised by homologous recombination repair deficiency (HRD), providing the rationale for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy ...

    • Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. 

      Brown, JS; O'Carrigan, B; Jackson, SP; Yap, TA (2017-01)
      Germline aberrations in critical DNA-repair and DNA damage-response (DDR) genes cause cancer predisposition, whereas various tumors harbor somatic mutations causing defective DDR/DNA repair. The concept of synthetic lethality ...

    • Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. 

      Vyse, S; Huang, PH (SPRINGERNATURE, 2019-03-08)
      Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic drivers in non-small cell lung cancer (NSCLC). ...

    • Targeting Endo180 with an antibody-drug conjugate for cancer treatment 

      Isacke C; Evans, R; Isacke, C (Institute of Cancer Research (University Of London), 2024-03-22)
      Antibody-drug conjugates (ADCs) are formed of an antibody attached to a cytotoxic drug via a linker which is cleaved upon internalisation of the ADC into the cell. This allows very toxic drugs to be directed to specific ...

    • Targeting folate receptor alpha for cancer treatment. 

      Cheung, A; Bax, HJ; Josephs, DH; Ilieva, KM; Pellizzari, G; et al. (IMPACT JOURNALS LLC, 2016-08-09)
      Promising targeted treatments and immunotherapy strategies in oncology and advancements in our understanding of molecular pathways that underpin cancer development have reignited interest in the tumor-associated antigen ...

    • Targeting HOX/PBX dimers in cancer. 

      Morgan, R; El-Tanani, M; Hunter, KD; Harrington, KJ; Pandha, HS (IMPACT JOURNALS LLC, 2017-05-09)
      The HOX and PBX gene families encode transcription factors that have key roles in establishing the identity of cells and tissues in early development. Over the last 20 years it has become apparent that they are also ...

    • Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome. 

      Salem, A; Asselin, M-C; Reymen, B; Jackson, A; Lambin, P; et al. (OXFORD UNIV PRESS INC, 2018-01-01)
      Oxygen deprivation (hypoxia) in non-small cell lung cancer (NSCLC) is an important factor in treatment resistance and poor survival. Hypoxia is an attractive therapeutic target, particularly in the context of radiotherapy, ...

    • Targeting molecular addictions in cancer. 

      Vivanco, I (NATURE PUBLISHING GROUP, 2014-11-25)
      Cancer cells depend on a finite number of critical signals for their survival. Oncogene addiction, that is, the acquired dependence of a cancer cell on the activity of a single oncogenic gene product, has been the basis ...

    • Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance. 

      Guo, C; Sharp, A; Gurel, B; Crespo, M; Figueiredo, I; et al. (NATURE PORTFOLIO, 2023-11-30)
      Inflammation is a hallmark of cancer1. In patients with cancer, peripheral blood myeloid expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter survival and treatment resistance across ...

    • Targeting NaPi2b in ovarian cancer. 

      Banerjee, S; Drapkin, R; Richardson, DL; Birrer, M (ELSEVIER SCI LTD, 2023-01-01)
      Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment ...

    • Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor. 

      Mathew, G; Hannan, A; Hertzler-Schaefer, K; Wang, F; Feng, G-S; et al. (2016-11)
      Deficiency in PTEN (phosphatase and tensin homolog deleted on chromosome 10) is the underlying cause of PTEN hamartoma tumor syndrome and a wide variety of human cancers. In skin epidermis, we have previously identified ...

    • Targeting PIK3CA-mutant advanced breast cancer in the clinical setting. 

      Chopra, N; Turner, NC (ELSEVIER SCIENCE INC, 2017-07-01)

    • Targeting radioresistance and replication fork stability in prostate cancer. 

      Li, X; Baek, G; Carreira, S; Yuan, W; Ma, S; et al. (AMER SOC CLINICAL INVESTIGATION INC, 2022-05-09)
      The bromodomain and extraterminal (BET) family of chromatin reader proteins bind to acetylated histones and regulate gene expression. The development of BET inhibitors (BETi) has expanded our knowledge of BET protein ...

    • Targeting RIPK1 ubiquitylation to promote anti-tumour immunity 

      Meier, P; Jamal, K; Meier, P (Institute of Cancer Research (University Of London), 2019-11-30)
      Cancer heterogeneity is a key problem of current therapies leading to resistance. The way cancer cells die can lead to anti-cancer immunity, which is frequently referred to as "immunogenic" cell death. The aim of the project ...

    • Targeting secondary protein complexes in drug discovery: studying the druggability and chemical biology of the HSP70/BAG1 complex. 

      Evans, LE; Jones, K; Cheeseman, MD (ROYAL SOC CHEMISTRY, 2017-05-04)
      Proteins typically carry out their biological functions as multi-protein complexes, which can significantly affect the affinity of small-molecule inhibitors. HSP70 is an important target in oncology, so to study its chemical ...

    • Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. 

      Pratt, AG; Siebert, S; Cole, M; Stocken, DD; Yap, C; et al. (ELSEVIER, 2021-05-01)
      BACKGROUND: Current rheumatoid arthritis therapies target immune inflammation and are subject to ceiling effects. Seliciclib is an orally available cyclin-dependent kinase inhibitor that suppresses proliferation of synovial ...

    • Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells. 

      Koo, C-Y; Giacomini, C; Reyes-Corral, M; Olmos, Y; Tavares, IA; et al. (AMER ASSOC CANCER RESEARCH, 2017-11-01)
      Thousand-and-one amino acid kinases (TAOK) 1 and 2 are activated catalytically during mitosis and can contribute to mitotic cell rounding and spindle positioning. Here, we characterize a compound that inhibits TAOK1 and ...

    • Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer. 

      Pacini, L; Jenks, AD; Lima, NC; Huang, PH (MDPI, 2021-05-10)
      Lung cancer is the most common cause of cancer-related deaths globally. Genetic alterations, such as amplifications, mutations and translocations in the fibroblast growth factor receptor (FGFR) family have been found in ...